GlassScriptPhysician profile
Maaz Sohail
NPI 1407242381
$5,756.39
in general payments reported to CMS, 2019-2025
27 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $410 · 2022: $290 · 2023: $1,386 · 2024: $1,759 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,543.37 |
| Education | $100.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,078.83 | 2022-2025 | Linzess, Rinvoq, Creon |
| Janssen Biotech, INC. | $850.49 | 2022-2025 | Tremfya, Stelara |
| Olympus Corporation of The Americas | $822.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.46 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $338.60 | 2022-2025 | Entyvio, Eohilia |
| Celgene Corporation | $336.36 | 2022-2024 | Zeposia |
| Pfizer INC. | $255.30 | 2023-2025 | |
| Genzyme Corporation | $248.42 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $214.07 | 2022-2024 | Tremfya |
| Qol Medical, LLC | $199.84 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $175.92 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $97.41 | 2023-2025 | Dupixent |
| Daiichi Sankyo INC. | $95.42 | 2024-2025 | Injectafer |
| Fresenius Kabi USA, LLC | $93.96 | 2023-2025 | Idacio |
| Gilead Sciences, INC. | $90.31 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $62.47 | 2025 | Rezdiffra |
| Lilly USA, LLC | $59.64 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $48.50 | 2023-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $44.28 | 2022-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $28.45 | 2024 | Iqirvo |
| Endogastric Solutions, INC | $23.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.84 | 2023 | Ocaliva |
| Organon LLC | $18.68 | 2023 | Renflexis |
| Celltrion USA INC. | $15.83 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $15.47 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $15.03 | 2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $14.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maaz Sohail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.